Weighing the evidence for CBD in pain and anxiety care

Community pharmacists across Australia are fielding more questions about cannabidiol than ever before. Walk into any dispensary in Melbourne or Brisbane and conversations at the counter are shifting from fish oil and magnesium to low-dose CBD oils, gummies and capsules marketed for everything from nerve pain to generalised anxiety. Many of these products sit outside the regulated prescription pathway, and patients arrive clutching bottles purchased online, often uncertain about what they contain or how they might interact with other medicines.

The Therapeutic Goods Administration has clarified much of the regulatory fog, but confusion persists. From February 2021, low-dose CBD preparations (up to 150 mg/day) were down-scheduled to Schedule 3, allowing pharmacist supply once a product is TGA-listed. Years later, no product has navigated that listing, so lawful access still requires a Schedule 4 prescription or the Special Access Scheme. The gap between what patients read online and what the law actually permits is where pharmacists spend much of their day.

This review summarises the current evidence for CBD in pain and anxiety management, examines the regulatory picture, and offers a framework for evidence-based conversations behind the pharmacy counter. It is written for practising pharmacists, pharmacy students and educators who want a clear summary of where the science actually sits, and where the marketing outruns the data.

Australian regulatory landscape for cannabidiol

The Australian framework for CBD is unusually strict by international comparison, which shapes both what pharmacists can recommend and what patients can lawfully buy. Most CBD products remain Schedule 4 prescription medicines, and any product with more than 150 mg per day sits in higher schedules. The TGA's 2020 interim decision to create a new Schedule 3 entry was widely reported, but the practical effect has been limited because no sponsor has yet met the requirements for an over-the-counter listing.

Access pathways therefore include the Special Access Scheme Category B, Authorised Prescriber schemes, and registered prescribing through GPs and specialists. In rural communities where prescriber access is thin, telehealth services have filled part of the gap. Some pharmacists have partnered with these services, and a recent commentary on leveraging telepharmacy to expand access in rural communities describes how that model works in practice.

Patients still buy unregulated products online or from wellness retailers, particularly in capital cities like Sydney and Perth where the market is more visible. Australian Bureau of Statistics data suggest the complementary medicines market exceeds A$5 billion annually, and a meaningful slice includes CBD products not assessed by the TGA. Pharmacists need to be ready to discuss both regulated and unregulated options.

Pharmacology and mechanism of action

CBD is one of more than 100 cannabinoids found in Cannabis sativa, and unlike tetrahydrocannabinol it does not produce intoxication. Its activity is complex and only partially mapped, with effects on serotonin 5-HT1A receptors, transient receptor potential channels, GPR55 receptors, and modulation of the endocannabinoid system through indirect action on CB1 and CB2 receptors. The clinical relevance of each pathway is still being worked out, and the absence of a single clean mechanism is one reason trial results are mixed.

Pharmacokinetically, oral CBD has low and variable bioavailability, often quoted between 6 and 19 percent depending on the formulation. It is highly lipophilic, extensively metabolised by the cytochrome P450 system (notably CYP3A4 and CYP2C19), and prone to drug interactions. Half-life is long and variable, ranging from 18 to 32 hours after multiple doses, which has implications for both steady-state timing and interaction screens.

These pharmacokinetic quirks matter at the dispensary bench. A patient in Adelaide asking about CBD for back pain may be unaware that their sertraline, clobazam or even omeprazole could be affected. Lipid-based formulations can improve absorption but also increase variability, and product-to-product differences in cannabinoid content have been documented in Australian and international analyses.

Evidence in chronic and neuropathic pain

The evidence for CBD alone in chronic non-cancer pain is modest at best. A 2021 systematic review in the BMJ that examined cannabinoids for pain found that most benefits were attributable to THC-containing products, and that non-intoxicating CBD alone showed little effect on pain scores in conditions such as osteoarthritis and chronic low back pain. Larger effects were seen in neuropathic pain, but the studies were small, often included THC co-administration, and used doses well above the 150 mg/day ceiling currently permitted for pharmacist supply in Australia.

For neuropathic conditions such as diabetic peripheral neuropathy and multiple sclerosis-related spasticity, the signal is somewhat stronger. Sativex, a buccal spray containing roughly equal parts CBD and THC, is approved in Australia for MS spasticity, but the relevant active for analgesia appears to be THC, and the evidence base for CBD alone in MS pain remains thin. A 2023 Cochrane review of cannabinoids for neuropathic pain concluded that any benefit came with meaningful increases in dizziness, sedation and gastrointestinal side effects.

In practical terms, a pharmacist in Hobart counselling a patient with persistent post-herpetic neuralgia should be honest about the limits of the evidence. Non-pharmacological measures, first-line neuropathic agents such as amitriptyline, gabapentin and duloxetine, and judicious use of topical lignocaine remain the better-supported options. CBD may be considered as an adjunct under medical supervision, but patients should not expect the dramatic relief implied by some online testimonials.

Evidence in anxiety disorders

The anxiety literature is more interesting, and the 5-HT1A activity of CBD provides a plausible biological mechanism. Several small randomised trials have examined single-dose CBD in experimental anxiety paradigms such as the simulated public speaking test, with reductions in subjective anxiety at doses between 300 and 600 mg. These studies are short-term, conducted in controlled settings, and used purified CBD rather than the oils and capsules sold in the Australian consumer market.

For clinical anxiety disorders, the data are more limited. A 2022 meta-analysis in the Journal of Clinical Psychiatry identified only a handful of adequately powered trials in generalised anxiety disorder, social anxiety disorder and post-traumatic stress disorder. Effect sizes were small to moderate, and study durations rarely extended beyond 12 weeks. Few of these trials used Australian populations, and the cultural and healthcare context in which anxiety is recognised and treated can differ substantially between trial sites and a suburban Sydney general practice.

Pharmacists in suburban Melbourne will recognise the patient profile: an adult with work-related stress, sometimes on an SSRI, often using alcohol or sleep aids, and now asking about CBD as a "natural" alternative. The honest answer is that the evidence does not yet support CBD as a primary treatment for any anxiety disorder, but for some patients who cannot tolerate first-line pharmacotherapy, a supervised trial may be reasonable. The same caveats around product quality, dose and drug interactions apply.

Product quality, dosing and the consumer market

One of the persistent challenges in counselling patients about CBD is the variability of consumer products. Independent testing of oils and capsules sold in Australia and overseas has repeatedly found discrepancies between labelled and actual cannabinoid content, with some products containing more THC than permitted and others almost no CBD at all. Without TGA-listed options, patients are largely navigating this landscape alone.

Dosing is another area of confusion. Patients in Brisbane will report anything from 5 mg per day for sleep to 200 mg per day for chronic pain, often with no clear rationale. The studies that do show benefit typically use divided daily doses of 300 mg or more for anxiety, and 300 to 1500 mg for refractory epilepsy, well above the levels in most consumer products. The "start low, go slow" principle applies, but the floor and ceiling remain poorly defined.

Pharmacists are well placed to provide clarity here. Recording brand, batch number, concentration and dose in the patient profile, even when the product is not on the dispensary shelf, builds a useful longitudinal record and helps identify patterns if adverse effects emerge. Where appropriate, a conversation about whether a regulated prescription product might offer more consistent dosing is worth raising.

Safety, adverse effects and drug interactions

CBD has a relatively favourable safety profile in healthy adults, but "natural" does not mean "harmless." Common adverse effects include somnolence, fatigue, diarrhoea and changes in appetite or weight. More concerning are the drug interactions, which are pharmacokinetic in most cases. CBD inhibits CYP2C19, CYP2C9 and CYP3A4, and can raise plasma concentrations of clobazam, valproate, warfarin, tacrolimus and many antidepressants, sometimes to clinically significant levels.

Hepatic effects also warrant attention. Elevated transaminases have been reported in clinical trials, particularly at higher doses and in patients with pre-existing liver disease. Baseline liver function tests and periodic monitoring may be appropriate for patients on long-term, high-dose CBD, and the pharmacist's role in prompting these checks should not be underestimated.

Practical counseling points for pharmacists

• Confirm whether the patient uses a TGA-regulated product or a consumer item, and document brand and dose.
• Screen for interactions with antidepressants, anticonvulsants, anticoagulants and proton pump inhibitors.
• Advise avoiding alcohol and operating heavy machinery until response is known.
• Encourage realistic expectations: pain relief is modest, anxiety benefits limited.

Common reasons for caution

• Concurrent benzodiazepines, where combined sedation can compound.
• Warfarin or direct oral anticoagulants, where INR or factor Xa levels may shift.
• Pregnancy or breastfeeding, for which the TGA advises against CBD use.
• Significant hepatic impairment, where clearance is reduced and liver enzymes may rise.

The pharmacist's role in evidence-based conversations

Pharmacists are among the few professionals who see patients at the point of decision-making, and that proximity carries responsibility. When a patient in Geelong asks whether the 30 mg/mL CBD oil they bought online is safe with their sertraline, the answer is rarely a simple yes or no. It requires a quick medication reconciliation, a check of the product's provenance, a discussion of the limited evidence, and a clear plan for follow-up.

Several professional organisations have begun issuing guidance. The Pharmaceutical Society of Australia has produced continuing professional development resources on medicinal cannabis, and the Pharmacy Guild of Australia has highlighted pharmacist responsibilities when supplying or counselling on these products. These resources are useful starting points, but they do not replace local clinical judgement.

There is also a broader role in advocacy and education. Pharmacists who understand the evidence are well placed to contribute to clinic audits, write for local health networks, or simply have more informed conversations with prescribers. A short piece by a colleague on patient-centred cannabis care illustrates the kind of reflective practice that elevates the conversation beyond product promotion.

If you are a pharmacist working in community practice, hospital or education, update your knowledge on the Australian framework, refresh your interaction screen, and rehearse a few plain-language explanations of what the evidence does and does not support. Patients trust pharmacists to translate complex science into practical advice, and CBD is one area where that translation is badly needed. Share this article with a colleague, leave a comment with the questions your patients ask most often, and contribute a short reflection for a future issue.